Professor, Preventive Medicine, Medicine, Medicine, Physiology

Office: 5159 Veterans Affairs Medical Center
Tel: (901) 577-7357


  • M.D., University of Mississippi School of Medicine, Jackson, Mississippi, Medicine
  • B.A., University of Mississippi at Oxford, MS, Chemistry and Biology


  1. Bakris, GL, Sica, D, White, WB, Cushman, WC, Weber, MA, Handley, A, Song, E, Kupfer, S. Antihypertensive Efficacy of Hydrochlorothiazide vs Chlorthalidone Combined with Azilsartan Medoxomil. Am J Med, 125 (12), 1229.e1-1229.e10, 2012.
  2. Proschan, M, Ford, CE, Cutler, JA, Graumlich, JF, Pavlik, V, Cushman, WC, Davis, BR, Alderman, MH, Gordon, D, Furberg, CD, Franklin, SS, Blumenthal, SS, Castaldo, RS, Preston, RA, ,. How much effect of different antihypertensive medications on cardiovascular outcomes is attributable to their effects on blood pressure. Stat Med, 2012.
  3. Cushman, WC. Getting to goal: how thiazide-type diuretics, following the guidelines, and improving patient adherence can help. Module 2: rethinking the role of thiazide-type diuretics in the management of hypertension: which diuretic is best. J Fam Pract, 61 (8 Suppl), S15-9, 2012.
  4. Ferrannini, E, Cushman, WC. Diabetes and hypertension: the bad companions. Lancet, 380 (9841), 601-10, 2012.
  5. Cushman, WC, Bakris, GL, White, WB, Weber, MA, Sica, D, Roberts, A, Lloyd, E, Kupfer, S. Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. Hypertension, 60 (2), 310-8, 2012.
  6. Barzilay, JI, Howard, AG, Evans, GW, Fleg, JL, Cohen, RM, Booth, GL, Kimel, AR, Pedley, CF, Cushman, WC. Intensive blood pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial. Diabetes Care, 35 (7), 1401-5, 2012.
  7. Krousel-Wood, M, Muntner, P, Carson, A, Anderson, AH, Delaune, E, Cushman, WC, Cutler, JA, Piller, LB, Goforth, GA, Whelton, PK. Hypertension control among newly treated patients before and after publication of the main ALLHAT results and JNC 7 guidelines. J Clin Hypertens (Greenwich), 14 (5), 277-83, 2012.
  8. Sica, D, Bakris, GL, White, WB, Weber, MA, Cushman, WC, Huang, P, Roberts, A, Kupfer, S. Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. J Clin Hypertens (Greenwich), 14 (5), 284-92, 2012.
  9. Walker, R, Hunt, YM, Olivier, J, Grothe, KB, Dubbert, PM, Burke, RS, Cushman, WC. Descriptive characteristics and cluster analysis of male veteran hazardous drinkers in an alcohol moderation intervention. Am J Addict, 21 (4), 335-42, 2012.
  10. Alderman, MH, Piller, LB, Ford, CE, Probstfield, JL, Oparil, S, Cushman, WC, Einhorn, PT, Franklin, SS, Papademetriou, V, Ong, ST, Eckfeldt, JH, Furberg, CD, Calhoun, DA, Davis, BR, ,. Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension, 59 (5), 926-33, 2012.
  11. Zannad, F, Stough, WG, Pocock, SJ, Sleight, P, Cushman, WC, Cleland, JG, McMurray, JJ, Lonn, E, Geller, NL, Wedel, H, Abadie, E, Alonso-Garcia, A, Pitt, B. Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements. Eur Heart J, 33 (9), 1049-57, 2012.
  12. Weintraub, HS, Duprez, DA, Cushman, WC, Zappe, DH, Purkayastha, D, Samuel, R, Izzo, JL. Antihypertensive response to thiazide diuretic or angiotensin receptor blocker in elderly hypertensives is not influenced by pretreatment plasma renin activity. Cardiovasc Drugs Ther, 26 (2), 145-55, 2012.
  13. Ismail-Beigi, F, Craven, TE, O'Connor, PJ, Karl, D, Calles-Escandon, J, Hramiak, I, Genuth, S, Cushman, WC, Gerstein, HC, Probstfield, JL, Katz, L, Schubart, U, ,. Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney Int, 81 (6), 586-94, 2012.
  14. Barzilay, JI, Davis, BR, Pressel, SL, Cutler, JA, Einhorn, PT, Black, HR, Cushman, WC, Ford, CE, Margolis, KL, Moloo, J, Oparil, S, Piller, LB, Simmons, DL, Sweeney, ME, Whelton, PK, Wong, ND, Wright, JT, ,. Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study. Circ Cardiovasc Qual Outcomes, 5 (2), 153-62, 2012.
  15. Cushman, WC, Davis, BR, Pressel, SL, Cutler, JA, Einhorn, PT, Ford, CE, Oparil, S, Probstfield, JL, Whelton, PK, Wright, JT, Alderman, MH, Basile, JN, Black, HR, Grimm, RH, Hamilton, BP, Haywood, LJ, Ong, ST, Piller, LB, Simpson, LM, Stanford, C, Weiss, RJ, ,. Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J Clin Hypertens (Greenwich), 14 (1), 20-31, 2012.
  16. Cushman, WC, Duprez, DA, Weintraub, HS, Purkayastha, D, Zappe, D, Samuel, R, Izzo, JL. Home and clinic blood pressure responses in elderly individuals with systolic hypertension. J Am Soc Hypertens, 6 (3), 210-8, 2012.
  17. Izzo, JL, Weintraub, HS, Duprez, DA, Purkayastha, D, Zappe, D, Samuel, R, Cushman, WC. Treating systolic hypertension in the very elderly with valsartan-hydrochlorothiazide vs. either monotherapy: ValVET primary results. J Clin Hypertens (Greenwich), 13 (10), 722-30, 2011.
  18. Piller, LB, Baraniuk, S, Simpson, LM, Cushman, WC, Massie, BM, Einhorn, PT, Oparil, S, Ford, CE, Graumlich, JF, Dart, RA, Parish, DC, Retta, TM, Cuyjet, AB, Jafri, SZ, Furberg, CD, Saklayen, MG, Thadani, U, Probstfield, JL, Davis, BR, ,. Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation, 124 (17), 1811-8, 2011.
  19. Duprez, DA, Weintraub, HS, Cushman, WC, Purkayastha, D, Zappe, D, Samuel, R, Izzo, JL. Effect of valsartan, hydrochlorothiazide, and their combination on 24-h ambulatory blood pressure response in elderly patients with systolic hypertension: a ValVET substudy. Blood Press Monit, 16 (4), 186-96, 2011.
  20. ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F.. Effects of intensive blood-pressure control in type 2 diabetes mellitus.. N Engl J Med, 362 (17), 1575-85, 2010.
  21. ACCORD Study Group; ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH, Goff DC Jr, Cushman WC, Ginsberg HN, Elam MB, Genuth S, Gerstein HC, Schubart U, Fine LJ.. Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes.. N Engl J Med, 363 (3), 233-244, 2010.